Endomagnetics Raises Further Funding for US Clinical Trial, Sales Support and New Product Development
Wednesday, 19 November, 2014
Endomagnetics, the Cambridge-based cancer healthcare company, has raised a further £2m ($3.12m US) to support its pivotal US clinical trial and the launch of a new cancer marker product in 2015.
The funds will also support market development beyond EMEA and Australasia, where the company...
Endomagnetics Completes Acquisition of the ACT Portfolio
Tuesday, 24 June, 2014
Endomagnetics, the company developing a portfolio of products to improve the standard of cancer care, announced today the acquisition of the ACT portfolio and related assets from Actium Biosystems, LLC. This move extends Endomagnetics’ oncology platform from diagnostics into therapeutics while...
Endomagnetics Introduces Higher Performance Probe and Makes CTO Appointment
Thursday, 29 May, 2014
Endomagnetics, the company developing a portfolio of products to improve the standard of cancer care, has developed a new, higher performance probe for its popular SentiMag® instrument.
The slimmer probe is only 18mm in diameter and has been designed in response to demand for minimal...
Another Major Award for Endomagnetics
Tuesday, 6 May, 2014
Endomagnetics has won the Midlands region ‘Best for Innovation’ award in the British Private Equity & Venture Capital Association (BVCA) Management Team Awards 2014. BVCA is the industry body for the private equity and venture capital industry in the UK.
The award to Endomagnetics...
Endomagnetics Wins Business Award for Best New Product
Wednesday, 19 March, 2014
Endomagnetics, the company enjoying international commercial success with its medical device technology, has been given the award for Best New Product or Business Model in this year’s Business Weekly awards. The award was made at a gala dinner at Queens’ College, Cambridge last night.